Publications by authors named "H Cheinquer"
Objective: The aim of this study was to evaluate the glycated hemoglobin (HbA1c) levels before and after sustained virologic response (SVR) and investigate the baseline characteristics associated with improved glycemic control in patients with chronic hepatitis C (CHC) achieving SVR after directacting antivirals (DAA) therapy.
Materials And Methods: Consecutive adult patients with CHC who achieved SVR after DAA treatment between January 2016 and December 2017 at Hospital de Clínicas de Porto Alegre (RS, Brazil) were prospectively included. Levels of HbA1c were measured up to 24 weeks before DAA therapy and 12 weeks after SVR.
The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis, we convene national experts from each of the top 20 highest burdened countries to provide an update on progress.
View Article and Find Full Text PDFArticle Synopsis
- Direct-acting antivirals have led to a rise in hepatocellular carcinoma (HCC) cases in patients who have achieved sustained virologic response (SVR) for hepatitis C, with limited understanding of regional differences in outcomes post-SVR HCC.
- A study of 8796 patients with advanced liver fibrosis found that 6.6% developed HCC, revealing significant geographic variations in detection, tumor size, and survival rates, with East Asia, North America, and South America having the best outcomes.
- The findings suggest that implementing HCC surveillance can lead to earlier detection and improved survival rates, highlighting its importance as an intervention strategy across different regions.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2020 the updated recommendations for the diagnosis and treatment of HCC. Since then, new data have emerged in the literature, including new drugs approved for the systemic treatment of HCC that were not available at the time.
View Article and Find Full Text PDFIntroduction And Objectives: With the advent of new therapeutic options for patients with hepatocellular carcinoma (HCC) for intermediate or advanced stages of the Barcelona Clinic Liver Cancer (BCLC), regional real-world data regarding prognostic survival factors are of significant importance.
Patients And Methods: A multicenter prospective cohort study was conducted in Latin America including BCLC B or C patients since 15 May 2018. We report here the second interim analysis focusing on prognostic variables and causes of treatment discontinuation.